Wall Street brokerages expect Arcturus Therapeutics Ltd (NASDAQ:ARCT) to post $4.68 million in sales for the current fiscal quarter, Zacks reports. Three analysts have made estimates for Arcturus Therapeutics’ earnings, with the highest sales estimate coming in at $5.04 million and the lowest estimate coming in at $4.50 million. Arcturus Therapeutics reported sales of $7.58 million in the same quarter last year, which indicates a negative year-over-year growth rate of 38.3%. The company is scheduled to report its next earnings report on Monday, March 16th.

According to Zacks, analysts expect that Arcturus Therapeutics will report full-year sales of $21.50 million for the current financial year, with estimates ranging from $18.75 million to $22.60 million. For the next fiscal year, analysts expect that the business will post sales of $15.10 million, with estimates ranging from $10.00 million to $20.30 million. Zacks’ sales averages are an average based on a survey of research firms that follow Arcturus Therapeutics.

A number of research analysts have issued reports on the stock. ValuEngine cut shares of Arcturus Therapeutics from a “sell” rating to a “strong sell” rating in a report on Wednesday, October 2nd. Zacks Investment Research raised shares of Arcturus Therapeutics from a “hold” rating to a “buy” rating and set a $13.00 target price for the company in a report on Tuesday, November 5th. Finally, HC Wainwright set a $18.00 target price on shares of Arcturus Therapeutics and gave the company a “buy” rating in a report on Friday, August 16th. One analyst has rated the stock with a sell rating and six have issued a buy rating to the company. The company has an average rating of “Buy” and an average target price of $16.33.

A number of institutional investors have recently modified their holdings of the business. ARK Investment Management LLC increased its holdings in Arcturus Therapeutics by 8.3% in the second quarter. ARK Investment Management LLC now owns 1,004,368 shares of the biotechnology company’s stock valued at $9,481,000 after buying an additional 77,224 shares in the last quarter. Dfpg Investments Inc. purchased a new position in Arcturus Therapeutics in the third quarter valued at about $4,802,000. Sumitomo Mitsui Trust Holdings Inc. increased its holdings in Arcturus Therapeutics by 129.7% in the third quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 298,530 shares of the biotechnology company’s stock valued at $3,066,000 after buying an additional 168,556 shares in the last quarter. Nikko Asset Management Americas Inc. increased its holdings in Arcturus Therapeutics by 129.7% in the third quarter. Nikko Asset Management Americas Inc. now owns 298,530 shares of the biotechnology company’s stock valued at $3,066,000 after buying an additional 168,556 shares in the last quarter. Finally, Highline Capital Management L.P. increased its holdings in Arcturus Therapeutics by 356.6% in the second quarter. Highline Capital Management L.P. now owns 217,866 shares of the biotechnology company’s stock valued at $2,057,000 after buying an additional 170,152 shares in the last quarter. 30.51% of the stock is owned by institutional investors.

NASDAQ:ARCT traded down $0.88 during mid-day trading on Wednesday, reaching $10.29. The stock had a trading volume of 97,700 shares, compared to its average volume of 65,937. The company has a debt-to-equity ratio of 2.43, a quick ratio of 2.51 and a current ratio of 2.51. The firm has a market capitalization of $168.95 million, a price-to-earnings ratio of -4.76 and a beta of 2.49. Arcturus Therapeutics has a twelve month low of $4.11 and a twelve month high of $15.50. The business has a 50 day simple moving average of $10.28 and a 200 day simple moving average of $9.73.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Ltd., an RNA medicines company, focuses on treatment of liver and respiratory diseases. The company's pipeline of RNA therapeutics include programs pursuing rare diseases, hepatitis B, non-alcoholic steatohepatitis, cystic fibrosis, and vaccines. The company owns LUNAR lipid-mediated delivery and Unlocked Nucleomonomer Agent (UNA) technology, including UNA Oligomers, which are covered by its patent portfolio, including 152 patents and patent applications issued in the United States, Europe, Japan, China, and internationally.

Read More: What is required to own or exchange cryptocurrency?

Get a free copy of the Zacks research report on Arcturus Therapeutics (ARCT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.